Sjögren’s Syndrome is easy to overlook or misdiagnose, making many patients feel frustrated. In this five-part video series, Dr. Alan Baer validates those who suffer from this disease, and informs those who don’t, about the common misconceptions and challenges that Sjögren’s patients face every day.
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a study drug in Subjects with Sjögren’s Syndrome
You could be eligible to participate in the SSAD clinical trial, to find out if the experimental drug is safe and effective in treating people with Sjögren’s Syndrome.
The trial is being sponsored by Elli Lilly and Company
Visit www.clinicaltrials.gov to learn about this study
Identifier: NCT02614716
What the study consists of:
- A screening that will be completed in 2 visits to review your medical history and determine if you are eligible to participate
- A treatment phase of 16 weeks duration
- Visits occur at every 2 or 4 weeks
- A post-treatment follow-up phase of 12 weeks
- The study is expected to last 28 weeks
Phase: 1
Study Type: Interventional
Study Design: Randomized
Principal Investigator:
Thomas Grader-Beck, MD, PhD
Study Visit Location:
The Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center
Johns Hopkins Bayview Medical Center
Baltimore, MD
For more information contact:
Ana Manzano
Research Program Coordinator
Telephone: 410-550-6492
A Study to Assess the Efficacy of RO5459072 in Participants with Sjögren’s Syndrome
You may be eligible to participate in a clinical research study involving an experimental drug. This clinical trial is currently recruiting participants to see how safe and effective an investigational drug, RO5459072 is in treating disease activity and symptoms of primary Sjögren’s Syndrome.
Visit www.clinicaltrials.gov to learn about this study
Registration Number: NCT02701985
Sponsor: F. Hoffman-La Roche, Ltd
Adults Eligible for Study: Ages 18 – 75 years
What the study consists of:
- A screening that will be completed in 2 visits to review your medical history and determine if you are eligible to participate
- A treatment phase of 12 weeks duration
- Study visits occur every 4 weeks
- A post-treatment follow-up phase
Phase: 2
Study Type: Interventional
Study Design: Randomized
Study #: IRB00098901
Principal Investigator:
Alan Baer, MD
The Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center
The Johns Hopkins Bayview Medical Center
Baltimore, MD 21224
For more information contact:
Ana Manzano
Research Program Coordinator
Telephone: 410-550-6492
Email: ana.manzano@jhmi.edu
